Liraglutide vs SLU-PP-332
Comparison of Liraglutide (High evidence) and SLU-PP-332 (Very Low evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Liraglutide
Dossier overview
SLU-PP-332
Dossier overview
Overview
Liraglutide and SLU-PP-332 are both studied in the peptide research space.
Liraglutide: The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014).
SLU-PP-332: A small molecule ERR (Estrogen-Related Receptor) agonist developed at Saint Louis University.
Evidence Comparison
| Aspect | Liraglutide | SLU-PP-332 |
|---|---|---|
| Evidence Level | High | Very Low |
| Human Studies | 58 | 0 |
| Preclinical Studies | 14 | 5 |
| Total Sources | 72 | 8 |
Key Differences
| Aspect | Liraglutide | SLU-PP-332 |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence Strength | High | Very Low |
| Total Sources | 72 | 8 |
| Human Studies | 58 | 0 |
Summary
- Liraglutide: High evidence with 72 total sources (58 human)
- SLU-PP-332: Very Low evidence with 8 total sources (0 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.